Novartis AG

Novartis AG

Novartis AG

Overview
Date Founded

1996

Headquarters

Lichtstrasse 35, Basel, 4056, CHE

Type of Company

Public

Employees (Worldwide)

106K

Industries

Pharmaceuticals
Medical Support Services
Hospitals & Patient Services
Wholesale: Consumer Non-Durables/Sundries
Biotechnology

Company Description

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Contact Data
Trying to get in touch with decision makers at Novartis AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Legal Officer

Chief Medical Officer

Chief Executive Officer, Sandoz

Head of Customer & Technology Solutions (CTS)

Global Head of Novartis Business Assurance & Advisory & Head of Internal Audit

Ad Interim Global Head of Strategy

Group Head of Corporate Affairs & Global Health

Board of Directors

Former Chief Operating Officer at Novartis Corporation

N at Novartis Corporation

Group Chief Executive Officer at Standard Chartered PLC

Scientific Founder at Blueprint Medicines Corp.

Former President of Beverages, Desserts & Post Cereal Division at The Kraft Heinz Co.

Former Chief Executive Officer at Chung's Foods

President & Chief Executive Officer at Koninklijke Philips NV

Executive Vice President Head of Strategic Business Units, Marketing, Sales & Nespresso at Nestlé SA

Dean at Duke University - School of Medicine

Partner at Lenz & Staehelin AG

Paths to Novartis AG
Potential Connections via
Relationship Science
You
Novartis AG
Owners & Shareholders
Details Hidden

UBS Asset Management Switzerland offers investment capabilities across all major traditional and alternative asset classes.

Details Hidden

WMC relies on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macro-analysts, quantitative analysts and technical analysts. Their portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team’s investment approach. WMC supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Details Hidden

CSAM Schweiz is an active manager which invests in equities and fixed-income across sectors and market-caps.

Recent Transactions
Details Hidden

Novartis AG purchases Cadent Therapeutics, Inc. from Cowen Investment Management LLC, Access Industries, Inc. - New York

Details Hidden

Novartis AG, Sandoz International GmbH purchase Glaxosmithkline Plc /Cephalosporin Antibiotics Business from GlaxoSmithKline Plc

Details Hidden

Siegfried Holding AG purchases Novartis /2 Manufacturing Sites from Novartis AG

Transaction Advisors
Legal Advisor

Advised onNovartis AG purchases Chiron Corp.

Accountant

Advised onNovartis AG purchases Chiron Corp.

Investment Advisor

Advised onNovartis AG purchases Alcon, Inc. from Nestlé SA

Legal Advisor

Advised onNovartis International AG, Novartis AG purchase AveXis, Inc.

Co-Chair, Corporate Group

Advised onNovartis AG purchases Alcon, Inc. from Nestlé SA

Legal Advisor

Advised onEli Lilly & Company purchases Elanco Tiergesundheit AG from Novartis AG

Advisors & Consultants
Consultant

The Energy Project energizes people and transforms companies, offering a detailed blueprint for fueling a fully engaged workforce. Drawing on the multidisciplinary science of high performance, we do this at three levels: We train people to perform sustainably at the highest levels by more skillfully managing their energy across four dimensions: physical, emotional, mental and spiritual to develop actionable strategies that help them to become more energized, focused and productive. We teach leaders to become Chief Energy Officers, who mobilize, inspire, focus, direct and regularly recharge the energy of those they lead. We partner with companies to help them better meet the core needs of their employees, so they’re freed, fueled and inspired to bring the best of themselves to work every day. Demand is exceeding our capacity. Time is the resource we’ve traditionally relied on to get more done. The problem with time is that it’s finite, and most of us no longer have additional hours left to invest at work. Energy, by contrast, can be expanded and regularly renewed. Drawing on the multidisciplinary science of high performance, The Energy Project has developed a set of simple principles and highly actionable practices for more effectively managing energy to drive higher levels of engagement, productivity, and innovation. Our clients range from companies such as Google, Coca Cola, Target, Sony, Ernst & Young, and Pfizer to organizations such as the Los Angeles Police Department, the Cleveland Clinic, Kipp Schools and many others.

Legal Advisor

Partner at Clifford Chance LLP

Legal Advisor

Partner at Winston & Strawn LLP

Legal Advisor

Partner at Winston & Strawn LLP

Clients

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. It operates through the following geographical segments: India, North America, Latin America, Europe, and Rest of the World. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines, sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Key Stats and Financials As of 2020
Market Capitalization
$201B
Total Enterprise Value
$222B
Earnings Per Share
$3.44
EBITDAMargin
35.52%
Enterprise Value / Sales
4.72x
Enterprise Value EBITDAOperating
13.28x
TEVNet Income
28.42x
Debt TEV
0.16x
Three Year Compounded Annual Growth Rate Of Revenue
-1.87%
Revenue
$47.2B
Net Profit
$7.82B
EBITDA
$16.8B
Total Debt
$34.6B
Total Equity
$51.7B
Investments
Details Hidden

Orna Therapeutics, Inc. is an American company located in Cambridge, MA. The firm develops mRNA therapeutics. It was founded by Alex Wesselhoeft, Daniel G. Anderson and Raffaella Squilloni. Thomas M. Barnes is currently the CEO of the company.The company says this about itself: Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. oRNA has many advantages over traditional mRNA approaches, including simplified production, improved formulatability, and superior protein expression – making it a highly disruptive, new class of RNA therapeutics with vast potential to change patient's lives

Details Hidden

Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.

Details Hidden

Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in Menlo Park, CA.

Investors
Details Hidden

Investor at Postmates LLC

Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

Suppliers
AptarGroup, Inc. Personal Products | Crystal Lake, IL

AptarGroup, Inc. develops manufactures and sales of consumer product dispensing systems. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sell dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust. It engages in the ownership, operation, development, and redevelopment of life science and technology properties. The firm also provides a space for lease to the life science and technology industries, which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Veeva Systems, Inc. Biotechnology | Pleasanton, CA

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage a regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. Veeva Systems was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Novartis AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Novartis AG's profile does not indicate a business or promotional relationship of any kind between RelSci and Novartis AG.